Pay in 4 interest-free payments of $6.43 Learn more
Ships within 48 hours · Estimated delivery Aug 14 - Aug 19
P.et al (2015)
Benefits follow a dose-dependent curve with optimal ranges identified in animal protocols
Nov 2023 - The FDA's approval of Eli Lillys Zepbound (tirzepatide) represents a significant advancement in obesity treatment, as it uniquely targets both GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 (glucagon-like peptide-1) hormone receptors
There are far more health-related topics covered within this book than its title implies
US$ 27.39
US$ 28.17
US$ 26.46
US$ 25.08
US$ 21.10
US$ 22.52
